The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized trial of radium-223 dichloride and cabozantinib in patients with advanced renal cell carcinoma (RCC) with osseous metastases (RADICAL/Alliance A031801).
 
Chinmay Jani
No Relationships to Disclose
 
Heather Jacene
Honoraria - Blue Earth Diagnostics; Munrol
Consulting or Advisory Role - spectrum dynamics
Research Funding - Blue Earth Diagnostics (Inst); Boston Scientific (I); Lantheus Medical Imaging (Inst)
Travel, Accommodations, Expenses - Abbott Laboratories (I); Abiomed (I); Biotronik International (I); Medtronic (I)
 
Pamela Atherton
No Relationships to Disclose
 
Archana Ajmera
No Relationships to Disclose
 
Tyler Zemla
No Relationships to Disclose
 
Ronald Chen
Employment - University of Kansas Medical Center
Consulting or Advisory Role - Abbvie; Accuray; Accuray; Astellas Pharma; Bayer; Blue Earth Diagnostics; Genentech; Janssen; Medivation/Astellas; Myovant Sciences; Pfizer; VIR Biotechnology; VIR Biotechnology
Research Funding - Accuray
Travel, Accommodations, Expenses - Reflexion Medical; Telix Pharmaceuticals
 
Atish Choudhury
Employment - LeMaitre Vascular (I)
Honoraria - Aptitude Health; Color Genomics; DAVA Oncology; Great Debates and Updates; Lantheus Medical Imaging; Medscape; OncLive; Outcomes4Me; Pfizer; Physicans' Education Resource; Springer; Targeted Oncology; Wiley
Consulting or Advisory Role - Astellas Pharma; Bayer; Boundless Bio; Daiichi Sankyo; Janssen Oncology; Johnson & Johnson/Janssen; Pfizer; Pfizer; Sanofi/Aventis; Tolmar; Tolmar
Research Funding - Bayer (Inst); Lilly (Inst); Pfizer (Inst); Pfizer (Inst); Sumitomo Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer
 
Joshua Lang
Consulting or Advisory Role - 4D Pharma; 4D Pharma; Arvinas; AstraZeneca; Foundation Medicine; Gilead Sciences; Immunomedics; Janssen; Macrogenics; Pfizer; Pfizer/Astellas; Pfizer/Myovant; Sanofi
Research Funding - Agensys (Inst); Arvinas (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Medivation (Inst)
Patents, Royalties, Other Intellectual Property - I am listed on the patent on a technology for rare cell capture and analysis. This technology has been licensed by Salus Discovery, LLC though no commercial products are available.
 
Suzanne Cole
Research Funding - Merck (Inst)
 
Tareq Al Baghdadi
No Relationships to Disclose
 
Young Kwok
No Relationships to Disclose
 
Alan Tan
Stock and Other Ownership Interests - Adaptimmune; Aprea AB; Bluebird Bio; Editas Medicine; FATE Therapeutics; Fusion Pharmaceuticals; ImmunityBio; Iovance Biotherapeutics; MEI Pharma; natera; RAPT Therapeutics
Honoraria - Bristol Myers Squibb Foundation; EMD Serono; Exelixis; Gilead Sciences; Merck; Myovant Sciences; natera; Seagen
Consulting or Advisory Role - Exelixis; Foundation Medicine; Myovant Sciences
Speakers' Bureau - bristol myers squibb; EMD Serono; Exelixis; Gilead Sciences; Merck; natera
 
Himisha Beltran
Consulting or Advisory Role - AstraZeneca; Bayer; Daicchi Sankyo; Merck; Novartis; Pfizer; Sanofi
Research Funding - Bristol Myers Squibb Foundation (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Michael Morris
Employment - Memorial Sloan-Kettering Cancer Center
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Ambrx; Amgen; Arvinas; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Clarity Pharmaceuticals; Convergent Therapeutics; Core Medica; Curium Pharma; Daiichi; Exelixis; Flare Therapeutics; Fusion Pharmaceuticals; ITM Isotope Technologies Munich; Lantheus Medical Imaging; Mashup Media; Pfizer; POINT Biopharma; Progenics; Telix Pharmaceuticals; Transtherabio; Z-Alpha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Janssen (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; APCCC; AstraZeneca; Memorial Sloan-Kettering Cancer Center
(OPTIONAL) Uncompensated Relationships - Amgen; Bayer; Halda Therapeutics; Janssen Oncology; Novartis; Wren Laboraties
 
Matthew Galsky
Consulting or Advisory Role - Abbvie; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Curis; Daiichi Sankyo Europe GmbH; EMD Serono; Gilead Sciences; Janssen; Merck; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Jonathan Rosenberg
Honoraria - MashupMD; NCCN/Pfizer; Pfizer; UpToDate
Consulting or Advisory Role - Aktis Oncology; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Century Therapeutics; EMD Serono; Generate Biomedicines; Gilead Sciences; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer; Roche/Genentech; Samsung Bioepis; Seagen; Tyra Biosciences
Research Funding - Acrivon Therapeutics; Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Lilly; Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Amplification of chromosome 1q23 to predict cancer outcomes (Inst); Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Seagen
(OPTIONAL) Uncompensated Relationships - Alliance for Clinical Trials in Oncology
 
Daniel George
Leadership - Capio BioSciences
Stock and Other Ownership Interests - Pfizer
Honoraria - American Association for Cancer Research; Astellas Pharma; AstraZeneca; Aveo; Axess Oncology; Bayer; Eisai; EMD Serono; Exelixis; IDEOlogy Health; Janssen Oncology; Merck; Millennium Medical Publishing; Myovant Sciences; Novartis; OncLive; Pfizer; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Exelixis; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Novartis; Pfizer; Physicans' Education Resource
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Expert Testimony - Exelixis
Travel, Accommodations, Expenses - Bayer; Exelixis; Merck; Novartis; Pfizer
 
Toni Choueiri
Leadership - ASCO
Stock and Other Ownership Interests - Abalytics Oncology; Bicycle Therapeutics; Curesponse; Faron Pharmaceuticals; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics
Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; MashupMD; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bicycle Therapeutics; Bristol-Myers Squibb; Clinical Care Options; Curesponse; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Neomorph; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - OTHER MEDICAL COMMUNICATION COMPANIES
 
Rana McKay
Consulting or Advisory Role - Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol Myers Squibb; Calithera Biosciences; Caris Life Sciences; Daiichi Sankyo; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; NeoMorph; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)